News and Analysis on Global Defense Defense, Technology, Warfare

Scientists test new prostate disease drug


Published: March 27, 2008 at 1:48 PM
Print story
Email to a friend
Font size:
QUEBEC CITY, March 27 (UPI) -- A Canadian-headquartered biopharmaceutical company is conducting the second Phase 3 study of a new drug designed to treat prostate disease.

Aeterna Zentaris Inc. said the double-blind study to be conducted in Europe will test the clinical effectiveness of cetrorelix, a luteinizing hormone-releasing drug for the treatment of benign prostatic hyperplasia, or BPH -- a non-cancerous enlargement of the prostate that causes disturbances in urination.

In the second Phase 3 study, 400 male patients will enter a four-week, no-treatment observation period and then be randomly assigned to either receive cetrorelix or a placebo. Effectiveness will based on a test that measures the severity and stability of voiding prostate symptoms.

The company's first study of the effectiveness of cetrorelix began in April 2007 and is continuing in Canada, Europe and the United States.

© 2008 United Press International. All Rights Reserved.
This material may not be reproduced, redistributed, or manipulated in any form.
Print story
Order reprints
Email to a friend
Post comment
See Also:
» Next in Science: NASA awards innovative research contract

CYCLONE MYANMUR
NASA's Terra satellite captured this image of the Burma coast on May 5, 2008, after Tropical Cyclone Nargis flooded the region on May 4, 2008. The death toll from the cyclone and its aftermath is feared to hit or exceed 100,000 lives. (UPI Photo/NASA/MODIS Rapid Response Team)
NASA satellite images reveal magnitude of flooding in Myanmar
Full Photo | Slideshow